Palleon Pharmaceuticals reports rapid remissions with HLX79/E-602 in Phase 2 kidney disease trial
Palleon's HLX79/E-602 achieved remission in all seven high-dose patients by Week 36. Can the small Phase 2 kidney trial support larger studies?
Pharma & Biotech
Pharma & Biotech
Palleon to present HLX79 and rituximab combination data at ACR Convergence 2026
Palleon Pharmaceuticals will present interim Phase 2 results for HLX79 plus a rituximab biosimilar in membranous nephropathy. A publicly available abstract reports 17 remissions among 26 patients, although the blinded analysis includes patients receiving rituximab without HLX79.
Pharma & Biotech
Genmab and AbbVie secure EU approval for Tepkinly in relapsed follicular lymphoma
Discover how Tepkinly’s EU approval could reshape second-line follicular lymphoma treatment and the safety and access questions still ahead.
Pharma & Biotech
Can Artiva Biotherapeutics, Inc. turn deep B-cell depletion into a scalable autoimmune treatment model?
Can AlloNK make autoimmune cell therapy scalable? Explore why Artiva Biotherapeutics, Inc.’s rheumatoid arthritis strategy matters.
Pharma & Biotech
ImmunityBio’s CAR-NK cell therapy achieves 15-month remission in Waldenström lymphoma
Find out how ImmunityBio’s CD19 CAR-NK cell therapy may change treatment for Waldenström lymphoma with durable responses and no chemotherapy.
Pharma & Biotech
Incyte’s Minjuvi combo gets Japan approval for relapsed follicular lymphoma
Incyte Biosciences Japan has secured approval from the Ministry of Health, Labour and Welfare for the use of Minjuvi (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma. This marks the first regulatory authorization in Japan for a CD19-directed therapy in this indication and introduces a novel CD19–CD20